{"component": "definition", "props": {"groups": [{"snippet": "and \u201cPhase C\u201d. Except as expressly set forth in Sections 1.2.2, 1.3 and 1.4, Landlord shall deliver each Phase of the Premises to Tenant in its then \u201cas-is\u201d condition without any representations or warranties regarding condition.", "snippet_links": [{"key": "phase-c", "type": "definition", "offset": [5, 12]}, {"key": "landlord-shall", "type": "clause", "offset": [77, 91]}, {"key": "phase-of", "type": "clause", "offset": [105, 113]}, {"key": "the-premises", "type": "clause", "offset": [114, 126]}, {"key": "to-tenant", "type": "clause", "offset": [127, 136]}, {"key": "representations-or-warranties", "type": "clause", "offset": [179, 208]}], "size": 4, "samples": [{"hash": "l9wo7L5xAPi", "uri": "/contracts/l9wo7L5xAPi#phase-b", "label": "Facility Lease Agreement", "score": 31.340862423, "published": true}, {"hash": "7iq7whDUcVt", "uri": "/contracts/7iq7whDUcVt#phase-b", "label": "Facility Lease Agreement (GT Advanced Technologies Inc.)", "score": 25.4572210815, "published": true}, {"hash": "l0DujzbC7VF", "uri": "/contracts/l0DujzbC7VF#phase-b", "label": "Facility Lease Agreement (GT Advanced Technologies Inc.)", "score": 24.8494182067, "published": true}], "hash": "235cf51db861514e5123a9b25e255460", "id": 1}, {"snippet": "means ***** as further described in SECTION 3.", "snippet_links": [{"key": "in-section-3", "type": "clause", "offset": [33, 45]}], "size": 3, "samples": [{"hash": "gbNwe9mC1D8", "uri": "/contracts/gbNwe9mC1D8#phase-b", "label": "License and Development Agreement", "score": 31.340862423, "published": true}, {"hash": "kJmvm5PQx5O", "uri": "/contracts/kJmvm5PQx5O#phase-b", "label": "License and Development Agreement (Affimed N.V.)", "score": 26.2265571526, "published": true}, {"hash": "3PyalUQi8n9", "uri": "/contracts/3PyalUQi8n9#phase-b", "label": "License and Development Agreement (Affimed Therapeutics B.V.)", "score": 25.4845995893, "published": true}], "hash": "d38f7f9ae22a6104491f53cbc4199e9b", "id": 2}, {"snippet": "means the Tender phase following the pre-qualification of Candidates until the end of the selection procedure of the Contractor which will establish the Organisation to enter into the Concession Agreement. This Phase consists of two stages: Stage \u0392.\u0399 - Dialogue; and Stage \u0392.\u0399\u0399 - Submission of Tender Offers.", "snippet_links": [{"key": "tender-phase", "type": "clause", "offset": [10, 22]}, {"key": "the-pre", "type": "clause", "offset": [33, 40]}, {"key": "selection-procedure", "type": "definition", "offset": [90, 109]}, {"key": "of-the-contractor", "type": "clause", "offset": [110, 127]}, {"key": "the-organisation", "type": "clause", "offset": [149, 165]}, {"key": "to-enter", "type": "definition", "offset": [166, 174]}, {"key": "concession-agreement", "type": "clause", "offset": [184, 204]}, {"key": "tender-offers", "type": "definition", "offset": [294, 307]}], "size": 2, "samples": [{"hash": "jHo6DoUvvFd", "uri": "https://minfin.gov.gr/wp-content/uploads/2023/09/%CE%94%CE%99%CE%91%CE%9A%CE%97%CE%A1%CE%A5%CE%9E%CE%97-%CE%943.2022-%CE%9C%CE%95-%CE%94%CE%99%CE%91%CE%A5%CE%93%CE%95%CE%99%CE%91-%CE%9A%CE%97%CE%9C%CE%94%CE%97%CE%A3.pdf", "label": "minfin.gov.gr", "score": 15.4368019825, "published": false}, {"hash": "2pVe6lMGb0o", "uri": "https://www.minfin.gr/documents/20182/17984801/%CE%A1%CE%A3%CE%A3%CE%92%CE%97-%CE%A6%CE%9D%CE%9E.pdf/552c3ee4-0671-4c7e-b204-68728e7742e4", "label": "www.minfin.gr", "score": 9.3696098563, "published": false}], "hash": "1668388bd175d886dadda14814dcfaff", "id": 3}, {"snippet": "shall have the meaning set forth in the Option Agreement.", "snippet_links": [{"key": "the-option-agreement", "type": "clause", "offset": [36, 56]}], "size": 2, "samples": [{"hash": "3w9HyiRaN2a", "uri": "/contracts/3w9HyiRaN2a#phase-b", "label": "Services Agreement (TEKMIRA PHARMACEUTICALS Corp)", "score": 25.2354551677, "published": true}, {"hash": "6hK5UkuaBd2", "uri": "/contracts/6hK5UkuaBd2#phase-b", "label": "Services Agreement (TEKMIRA PHARMACEUTICALS Corp)", "score": 25.0602327173, "published": true}], "hash": "7632ab50a830b0fc1fd93cff113e6aac", "id": 4}, {"snippet": "is defined in the 2021 State Assistance Agreement.", "snippet_links": [{"key": "assistance-agreement", "type": "definition", "offset": [29, 49]}], "size": 2, "samples": [{"hash": "gUljDlGpBcm", "uri": "/contracts/gUljDlGpBcm#phase-b", "label": "Property Disposition and Development Agreement", "score": 31.7244072873, "published": true}, {"hash": "587OSLvHHO1", "uri": "/contracts/587OSLvHHO1#phase-b", "label": "Property Disposition and Development Agreement", "score": 31.7244072873, "published": true}], "hash": "498424b4a936129474a6bfd3f5a46b1f", "id": 5}, {"snippet": "means, under each Program, [***] of this Agreement.", "snippet_links": [{"key": "this-agreement", "type": "clause", "offset": [36, 50]}], "size": 2, "samples": [{"hash": "kckpE6TS4II", "uri": "/contracts/kckpE6TS4II#phase-b", "label": "Collaboration and License Agreement (Pieris Pharmaceuticals, Inc.)", "score": 26.2402464066, "published": true}, {"hash": "1NM8pwgaDku", "uri": "/contracts/1NM8pwgaDku#phase-b", "label": "Collaboration and License Agreement (Marika Inc.)", "score": 25.9609856263, "published": true}], "hash": "fe0246bae312b87d77cdaa9e22d34710", "id": 6}, {"snippet": "means the activities outlined in the Research Plan to be commenced pursuant Section 2(e)(iii).", "snippet_links": [{"key": "the-activities", "type": "clause", "offset": [6, 20]}, {"key": "research-plan", "type": "clause", "offset": [37, 50]}], "size": 2, "samples": [{"hash": "1qaDMoA9cei", "uri": "/contracts/1qaDMoA9cei#phase-b", "label": "Option Agreement (TEKMIRA PHARMACEUTICALS Corp)", "score": 25.2354551677, "published": true}, {"hash": "lrfa2FoIlS1", "uri": "/contracts/lrfa2FoIlS1#phase-b", "label": "Option Agreement (TEKMIRA PHARMACEUTICALS Corp)", "score": 25.0602327173, "published": true}], "hash": "1b811adf7985cb3f26dcc8935f5f325b", "id": 7}, {"snippet": "means, for each Program relating to a DS Target, the period [***].", "snippet_links": [{"key": "relating-to", "type": "definition", "offset": [24, 35]}, {"key": "the-period", "type": "clause", "offset": [49, 59]}], "size": 2, "samples": [{"hash": "dspRfT21nUx", "uri": "/contracts/dspRfT21nUx#phase-b", "label": "Collaboration Research and Technology Licensing Agreement (Pieris Pharmaceuticals, Inc.)", "score": 26.2402464066, "published": true}, {"hash": "jODfUt72dJh", "uri": "/contracts/jODfUt72dJh#phase-b", "label": "Collaboration Research and Technology Licensing Agreement (Marika Inc.)", "score": 25.9609856263, "published": true}], "hash": "dd18d93bee81c83e88a1295d0c08fa90", "id": 8}, {"snippet": "means the activities outlined in the Research Plan to be commenced pursuant to Section 2(e)(iii) of the Option Agreement.", "snippet_links": [{"key": "the-activities", "type": "clause", "offset": [6, 20]}, {"key": "research-plan", "type": "clause", "offset": [37, 50]}, {"key": "pursuant-to-section", "type": "clause", "offset": [67, 86]}, {"key": "the-option-agreement", "type": "clause", "offset": [100, 120]}], "size": 2, "samples": [{"hash": "gw7i4HxNZAQ", "uri": "/contracts/gw7i4HxNZAQ#phase-b", "label": "License and Services Agreement (TEKMIRA PHARMACEUTICALS Corp)", "score": 25.2354551677, "published": true}, {"hash": "j5Jc71noz5q", "uri": "/contracts/j5Jc71noz5q#phase-b", "label": "License and Services Agreement (TEKMIRA PHARMACEUTICALS Corp)", "score": 25.0602327173, "published": true}], "hash": "2e4957ad63677267799033749da2e1ac", "id": 9}, {"snippet": "means the preclinical and clinical development phase pursuant to Section 3.", "snippet_links": [{"key": "development-phase", "type": "definition", "offset": [35, 52]}, {"key": "pursuant-to-section-3", "type": "clause", "offset": [53, 74]}], "size": 1, "samples": [{"hash": "k8LlMYswAdE", "uri": "/contracts/k8LlMYswAdE#phase-b", "label": "License and Collaboration Agreement (BioNTech SE)", "score": 34.2320328542, "published": true}], "hash": "400407f1dc6efefc5c16b4ed8c04882b", "id": 10}], "next_curs": "ClQSTmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjALEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIQcGhhc2UtYiMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"title": "Phase B", "snippet": "and \u201cPhase C\u201d. Except as expressly set forth in Sections 1.2.2, 1.3 and 1.4, Landlord shall deliver each Phase of the Premises to Tenant in its then \u201cas-is\u201d condition without any representations or warranties regarding condition.", "size": 34, "id": "phase-b", "examples": ["The conceptual development plan and lotting diagram for <strong>Phase B</strong> of the Development (the \u201cLotting Diagram\u201d) are attached hereto as Exhibit A and incorporated herein by this reference.", "Certain alleys, walkways, landscape tracts, and other private improvements will serve the Property and may also serve lots acquired by other builders within <strong>Phase B</strong>.", "Memorandum of understanding for a coopera- tive program concerning design (<strong>Phase B</strong>) of a permanently manned space station.", "The species that are invasive to grassland habitats are not a threat to the long-term viability of the CSS and riparian habitats within the <strong>Phase B</strong> mitigation area and will not be subject to removal on a continuous basis.", "TIAS Memorandum of understanding for a coopera- tive program concerning design (<strong>Phase B</strong>) of a permanently manned space station.", "While ADOLOR is licensed under <strong>Phase B</strong>, ADOLOR shall have the same rights to participate in actions to terminate an infringement of \u2587\u2587\u2587\u2587\u2587\u2587\u2587 Technical Information as \u2587\u2587\u2587\u2587\u2587\u2587\u2587 has with respect to Lilly Intellectual Property Rights under the Lilly License.", "The initial Development Plan describing the services to be performed by Affimed during <strong>Phase B</strong> is attached hereto as Annex 1.", "Either Party may recommend changes to the Development Plan at any time, provided that such changes shall only be effective upon the written approval of the Company and Affimed and, provided, further, that any such changes relating to the specifications to be met by the Lead Candidates, Development Candidate(s) and Back-Up Candidate(s) in <strong>Phase B</strong> shall also require the prior written approval of \u2587\u2587\u2587\u2587\u2587\u2587\u2587.", "The term of the license shall be either the term of Phase A or, if ADOLOR elects to proceed with <strong>Phase B</strong>, the sum of the terms of Phase A and <strong>Phase B</strong>.", "The goal of Phase A is to jointly discover, research and develop in accordance with the Research Plan, Clinical Candidates against the Target Combinations for further preclinical and clinical development in <strong>Phase B</strong>, on the basis of a 50/50 cost sharing."], "related": [["phase-1", "Phase 1", "Phase 1"], ["phase-2", "Phase 2", "Phase 2"], ["phase-ii", "Phase II", "Phase II"], ["phase-iii", "Phase III", "Phase III"], ["study-completion", "Study Completion", "Study Completion"]], "related_snippets": [], "updated": "2025-07-06T21:58:41+00:00"}, "json": true, "cursor": ""}}